Scholarlink

Objective <p>Liriodenine, a natural aporphine alkaloid from various medicinal plants, has shown antitumor activity in several cancers. However, its role and mechanisms in non-small cell lung cancer (NSCLC) remain unclear.</p> Methods <p>Potential targets of liriodenine and NSCLC were retrieved from public databases. Core targets were identified using random forest and the Least Absolute Shrinkage and Selection Operator regression algorithms. Molecular docking and dynamics simulations assessed the binding affinity and stability between liriodenine and its targets. In vitro assays were performed in A549 cells. Cell viability, proliferation, migration, and apoptosis were evaluated by CCK-8, colony formation, wound healing, and flow cytometry, respectively. Western blot was used to measure Transforming Growth Factor Beta 1(TGF-β1)expression.</p> Results <p>Sixty-five overlapping targets were identified. Computational analysis showed that liriodenine strongly and stably binds TGF-β1. In vitro, liriodenine significantly inhibited proliferation and migration, induced apoptosis, and downregulated TGF-β1 expression in a dose-dependent manner. These effects provide evidence suggesting the involvement of the TGF-β1/Epithelial-Mesenchymal Transition pathway.</p> Conclusion <p>This study provides both computational and experimental evidence that liriodenine inhibits the growth and migration of NSCLC cells and promotes apoptosis by suppressing TGF-β1. These findings highlight its potential as a natural candidate for targeted therapy against NSCLC.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Network pharmacology analysis and in vitro experimental validation of liriodenine against non-small cell lung cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月26日

查看全文
  • Jing Yang,
  • Yichu Sun,
  • Fei Liang,
  • Ziqiang Shen,
  • Yun Zhou,
  • Jiangrui Zhu,
  • Wen Sun,
  • Youyou Xia

摘要

Objective

Liriodenine, a natural aporphine alkaloid from various medicinal plants, has shown antitumor activity in several cancers. However, its role and mechanisms in non-small cell lung cancer (NSCLC) remain unclear.

Methods

Potential targets of liriodenine and NSCLC were retrieved from public databases. Core targets were identified using random forest and the Least Absolute Shrinkage and Selection Operator regression algorithms. Molecular docking and dynamics simulations assessed the binding affinity and stability between liriodenine and its targets. In vitro assays were performed in A549 cells. Cell viability, proliferation, migration, and apoptosis were evaluated by CCK-8, colony formation, wound healing, and flow cytometry, respectively. Western blot was used to measure Transforming Growth Factor Beta 1(TGF-β1)expression.

Results

Sixty-five overlapping targets were identified. Computational analysis showed that liriodenine strongly and stably binds TGF-β1. In vitro, liriodenine significantly inhibited proliferation and migration, induced apoptosis, and downregulated TGF-β1 expression in a dose-dependent manner. These effects provide evidence suggesting the involvement of the TGF-β1/Epithelial-Mesenchymal Transition pathway.

Conclusion

This study provides both computational and experimental evidence that liriodenine inhibits the growth and migration of NSCLC cells and promotes apoptosis by suppressing TGF-β1. These findings highlight its potential as a natural candidate for targeted therapy against NSCLC.